The UGT1A1 genotype also influences the pharmacokinetics of other glucuronidation-dependent drugs – including several ones used in ALL treatment (e.g., methotrexate, etoposide, and cyclophosphamide) [28, 32, 33, 35, 46, 47]. This evidence concerns the gene UGT1A1 and acute lymphoblastic leukemia.